Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Andrew Obenshain | President, CEO & Director | 20.65M | -- | 1974 |
| Mr. Thomas J. Klima | Chief Commercial Officer & COO | 13.39M | -- | 1972 |
| Mr. Richard A. Colvin M.D., Ph.D. | Chief Medical Officer | 13.68M | -- | 1966 |
| Mr. Oliver James Sterling III | CFO & Principal Accounting Officer | -- | -- | -- |
| Mr. Joseph D. Vittiglio Esq., J.D. | Chief Legal & Business Officer and Secretary | -- | -- | 1972 |
| Jess Rowlands | Head of Corporate Communications | -- | -- | -- |
| Ms. Andrea Walton | Chief People Officer | -- | -- | -- |
| Mr. Kasra Kasraian | Senior Vice President of Technical Development & Operations | -- | -- | -- |
| Mr. Scott Shoemaker | Senior Vice President of Quality | -- | -- | -- |
| Ms. Sarah Alspach | Senior Vice President of External Affairs | -- | -- | -- |
bluebird bio, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 375
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
Corporate Governance
Upcoming Events
March 24, 2025 at 12:30 PM UTC - March 28, 2025 at 12:30 PM UTC
bluebird bio, Inc. Earnings Date
Recent Events
Recent Events Information Not Available